<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00902291</url>
  </required_header>
  <id_info>
    <org_study_id>2008002</org_study_id>
    <secondary_id>2009-009194-99</secondary_id>
    <nct_id>NCT00902291</nct_id>
  </id_info>
  <brief_title>A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer</brief_title>
  <official_title>A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agensys, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate AGS-1C4D4 administered in combination with Gemcitabine chemotherapy in
      subjects with Metastatic Pancreatic Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A disease assessment will be performed at study week 8 (± 3 days) by the investigator. The
      assessment will be based both on changes in clinical symptoms, and radiographic images.
      Subjects without evidence of disease progression may continue to receive treatment based on
      their original treatment assignment until disease progression or intolerability. Disease
      assessments will be performed every 8 weeks during the extended period. A safety follow-up
      visit will occur 4 weeks after the last dose infusion of AGS-1C4D4 and/or gemcitabine.

      Post-Treatment: Subjects terminating from protocol therapy for reasons unrelated to
      documented disease progression will be followed by telephone contact every 2 months until
      they begin a new anticancer therapy, their disease progresses, they die, become lost to
      follow-up or withdrawal consent for further follow-up, whichever of these events occurs
      first.

      Overall survival: All subjects will be followed by telephone contact every 2 months until
      death, loss to follow-up, or withdrawal of consent, whichever of these events occurs first.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival rate at 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Throughout treatment period and post-treatment every 2 months until death, or subject discontinues the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Throughout treatment period or post-treatment every 2 months until disease progression or death, respectively, or subject discontinues the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in level of serum tumor marker CA 19-9</measure>
    <time_frame>Week 1, Week 4, Week 7 and every 3 weeks during the extended treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-AGS-1C4D4 antibody formation</measure>
    <time_frame>Week 1, Week 7 and every 8 weeks during the extended treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (Partial Response or better per RECIST criteria version 1.1</measure>
    <time_frame>Week 8, and every 8 weeks during the extended treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control (Stable Disease or better per RECIST criteria)</measure>
    <time_frame>Week 8, and every 8 weeks during the extended treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">205</enrollment>
  <condition>Carcinoma, Pancreatic Ductal</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Pancreatic Disease</condition>
  <arm_group>
    <arm_group_label>1. Gemcitabine monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Gemcitabine plus AGS-1C4D4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AGS-1C4D4</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>2. Gemcitabine plus AGS-1C4D4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>1. Gemcitabine monotherapy</arm_group_label>
    <arm_group_label>2. Gemcitabine plus AGS-1C4D4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed metastatic adenocarcinoma of the pancreas (AJCC Stage IV).
             Subjects with islet cell neoplasms are excluded

          -  Non-measurable or measurable disease based on the RECIST criteria

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

          -  Life expectancy of &gt; 3 months

          -  Hematologic function, as follows:

               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

               -  Platelet count ≥ 100 x 109/L

               -  Hemoglobin ≥ 9 g/dL (transfusion independent)

          -  Renal function, as follows:

               -  Creatinine ≤ 2.0 mg/dL

          -  Hepatic function, as follows:

               -  Aspartate aminotransferase (AST) ≤ 2.5 x ULN or ≤ 5 x ULN if known liver
                  metastases.

               -  Alanine aminotransferase (ALT) ≤ 2.5 x ULN or ≤ 5 x ULN if known liver metastases

               -  Bilirubin ≤ 2 x ULN

          -  INR &lt; 1.3 (or ≤ 3 if on warfarin for therapeutic anti-coagulation)

        Exclusion Criteria:

          -  Prior systemic therapy for metastatic pancreatic cancer

               -  Subjects who have received adjuvant treatment with gemcitabine and who had
                  relapse metastatically are allowed

               -  Subjects with advanced local disease who have received treatment with gemcitabine
                  and in whom progression has been observed with the onset of metastases less than
                  6 months are excluded

          -  Chemotherapy and/or radiation within 4 weeks of study enrollment

          -  Prior monoclonal antibody therapy within 60 days of study enrollment

          -  Known brain or leptomeningeal disease

          -  History of other primary malignancy, unless:

               -  Curatively resected non-melanomatous skin cancer

               -  Other malignancy curatively treated with no known active disease present and no
                  treatment administered for the last 3 years

          -  Active angina or Class III or IV Congestive Heart Failure (New York Heart Association
             CHF Functional Classification System)

          -  Use of any investigational product within 4 weeks of study enrollment

          -  Major surgery (that requires general anesthesia) within 4 weeks before study
             enrollment

          -  Women who are pregnant (confirmed by positive pregnancy test) or lactating

          -  Man or woman of childbearing potential not consenting to use adequate contraceptive
             precautions during the course of the study and for 4 weeks after the last AGS-1C4D4
             and/or gemcitabine infusion administration

          -  Subject known to be human immunodeficiency, hepatitis B or hepatitis C virus positive

          -  Active serious infection not controlled with antibiotics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Agensys, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Diego Medical Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Institute of Hematology and Oncology</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology LLC</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Annapolis Oncology Center</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia G. Piper Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Oncology Center</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Northwest Region Oncology Hematology</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of the Carolinas</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Regional Cancer Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center, Div. of Medical Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alan B. Pearson Regional Cancer Center Lynchburg Hematology Oncology Clinic</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Bernard, Oncologie médicale</name>
      <address>
        <city>Le Mans Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Régional de Lutte Contre le Cancer-Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital du Haut Lèvêque, Service d'Hepato Gastroentérologie</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Poitiers</name>
      <address>
        <city>Poitiers Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution of Healthcare &quot;Arkhangelsk Regional Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Oncology Dispensary</name>
      <address>
        <city>Ivanovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Oncology Dispensary of Republic of Tatarstan</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution &quot;Leningrad Regional Oncologic Dispensary&quot;</name>
      <address>
        <city>Kuzmolovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-state Healthcare Institution N.A. Semashko Central Clinical Hospital #2 of JSC &quot;Russian Railway&quot;</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Radiology Research Center of Russian Medical Academy</name>
      <address>
        <city>Obninsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution of Omsk Region &quot;Clinical Oncologic Dispensary&quot;</name>
      <address>
        <city>Omsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution &quot;S.M. Kirov Military Medical Academy of Ministry of Defense of Russia&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Healthcare Institution &quot;Municipal Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona, Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud, Servicio Oncologia</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=1034</url>
    <description>Link to Results on JAPIC</description>
  </link>
  <reference>
    <citation>Wolpin BM, O'Reilly EM, Ko YJ, Blaszkowsky LS, Rarick M, Rocha-Lima CM, Ritch P, Chan E, Spratlin J, Macarulla T, McWhirter E, Pezet D, Lichinitser M, Roman L, Hartford A, Morrison K, Jackson L, Vincent M, Reyno L, Hidalgo M. Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Ann Oncol. 2013 Jul;24(7):1792-801. doi: 10.1093/annonc/mdt066. Epub 2013 Feb 28.</citation>
    <PMID>23448807</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2009</study_first_submitted>
  <study_first_submitted_qc>May 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2009</study_first_posted>
  <disposition_first_submitted>May 23, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>May 23, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 5, 2013</disposition_first_posted>
  <last_update_submitted>August 31, 2015</last_update_submitted>
  <last_update_submitted_qc>August 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clinical Trial, Phase II</keyword>
  <keyword>Combination Drug Therapy</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>AGS-1C4D4</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Pancreatic Diseases</mesh_term>
    <mesh_term>Carcinoma, Pancreatic Ductal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

